Table.

Change from baseline in RAPID3 at Wk 12 in SELECT-BEYOND and -COMPARE, and Wk 14 in SELECT-MONOTHERAPY

Phase III studyGroupNMean (SD) change from BL
SELECT-BEYOND (bDMARD-IR)PBO148-3.5 (7.1)
UPA 15 mg QD159-6.9 (6.7)
UPA 30 mg QD150-7.4 (6.9)
SELECT-COMPARE (MTX-IR)PBO616-4.2 (6.4)
UPA 15 mg QD613-8.6 (6.6)
ADA 40 mg EOW307-7.0 (6.1)
SELECT-MONOTHERAPY (MTX-IR)cMTX203-3.5 (6.5)
UPA 15 mg QD201-7.2 (7.1)
UPA 30 mg QD205-8.5 (6.3)
  • ADA, adalimumab; bDMARD, biologic disease-modifying antirheumatic drug; BL, baseline; MTX, methotrexate; IR, inadequate response; PBO, placebo; QD, once daily; SD, standard deviation; UPA, upadacitinib